Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Cancer Chemotherapy and Pharmacology
|
January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
Jeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
Physical Review Letters
|
July 23, 2016
Displacement of Propagating Squeezed Microwave States
Kirill G Fedorov, L Zhong, S Pogorzalek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
Kwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
JCO Oncology Practice
|
December 11, 2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
Julia Blanter, Grace Van Hyfte, Maham Ahmad, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Cancer Chemotherapy and Pharmacology
|
January 12, 2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
Jeffrey A Meyerhardt, Jeffrey W Clark, Jeffrey G Supko, et al.
Physical Review Letters
|
July 23, 2016
Displacement of Propagating Squeezed Microwave States
Kirill G Fedorov, L Zhong, S Pogorzalek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R Hui, E B Garon, J W Goldman, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
Kwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
JCO Oncology Practice
|
December 11, 2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
Julia Blanter, Grace Van Hyfte, Maham Ahmad, et al.
Page
of 12